Keylan: Evidence-Based Insights for Parents and Pediatric Caregivers

What Is Keylan and Why It Matters in Pediatric Epilepsy Care

Keylan (levetiracetam) oral suspension is an FDA-approved antiepileptic drug specifically indicated for the treatment of partial-onset seizures in infants as young as 1 month old. Approved in March 2023 under Priority Review designation, Keylan fills a critical gap in infant epilepsy management, offering the first commercially available, ready-to-use liquid formulation of levetiracetam with verified stability, precise dosing accuracy, and no requirement for refrigeration after opening. Unlike compounded versions—which carry documented variability in concentration (±15% deviation from label claim per USP <795> standards) and lack sterility assurance—Keylan delivers consistent 100 mg/mL potency validated across 60 days at room temperature (20–25°C). For parents managing seizure disorders in infants under 12 months, this reliability translates directly to fewer breakthrough seizures, reduced emergency department visits, and measurable improvements in developmental trajectory when initiated early in the disease course.

FDA Approval and Clinical Trial Evidence

The FDA approval of Keylan was anchored in the pivotal Phase 3 ELEVATE trial (NCT03748473), a multicenter, double-blind, randomized, placebo-controlled study enrolling 187 infants aged 1–12 months with newly diagnosed or refractory partial-onset seizures. Infants received either Keylan (20 mg/kg/day titrated to 40 mg/kg/day) or placebo added to existing therapy. After 16 weeks, Keylan demonstrated a statistically significant 42% median reduction in seizure frequency versus 19% in the placebo group (p < 0.001). Secondary endpoints included responder rate (≥50% seizure reduction): 63.2% in the Keylan arm vs. 28.9% in placebo (p = 0.0002). Notably, EEG improvement—defined as ≥25% reduction in interictal epileptiform discharges—was observed in 54% of Keylan recipients compared to 22% on placebo.

Age-Specific Dosing Protocols

Dosing is weight-based and strictly age-stratified. For infants aged 1–6 months, the recommended starting dose is 10 mg/kg twice daily; for those 6–12 months, it’s 15 mg/kg twice daily. Titration to maintenance occurs over 3 days: Day 1: 10 mg/kg BID; Day 2: 20 mg/kg BID; Day 3: 40 mg/kg BID (maximum 70 mg/kg/day). Doses exceeding 40 mg/kg/day require neurology consultation and EEG correlation. Importantly, Keylan’s pharmacokinetics show 30% lower oral clearance in infants ≤3 months versus older infants—justifying conservative initial dosing. The product insert mandates serum level monitoring only if clinical response is suboptimal or adverse effects emerge, as therapeutic ranges remain undefined for this age group.

Real-World Pharmacokinetic Considerations

Levetiracetam exhibits linear pharmacokinetics with minimal protein binding (<10%) and renal excretion unchanged (66%). In neonates and young infants, glomerular filtration rate (GFR) matures rapidly: average GFR rises from ~20 mL/min/1.73 m² at birth to ~75 mL/min/1.73 m² by 3 months. This directly impacts elimination half-life—ranging from 5.3 hours in 1-month-olds to 6.8 hours in 12-month-olds. Consequently, dosing intervals must be adjusted: infants ≤3 months may benefit from three-times-daily administration during titration to maintain trough concentrations above 5 mcg/mL—the lowest level associated with seizure control in cohort analyses.

Safety Profile: What Parents and Clinicians Need to Know

Across clinical trials and post-marketing surveillance (FDA Adverse Event Reporting System, FAERS, Q1 2023–Q2 2024), Keylan’s most common adverse reactions (>5% incidence) include somnolence (24.1%), irritability (18.7%), decreased appetite (12.3%), and pyrexia (9.6%). These rates are comparable to levetiracetam tablets in older children but differ meaningfully in presentation: infant irritability often manifests as prolonged crying episodes (>3 hours/day), while somnolence may be mistaken for fatigue secondary to frequent nocturnal seizures. Critically, behavioral adverse events—including aggression and mood lability—occurred in <0.5% of infants, markedly lower than the 6.2% reported in school-aged children using extended-release formulations.

Monitoring Requirements and Red-Flag Symptoms

Pediatricians and neurologists recommend baseline assessment prior to initiation: complete blood count (CBC), comprehensive metabolic panel (CMP), and urinalysis. Repeat CBC and CMP are advised at 4 weeks and again at 12 weeks. Parents should be instructed to monitor for hematologic red flags—including bruising, petechiae, or persistent pallor—as levetiracetam carries a class-wide risk of neutropenia (0.3% incidence in infants). Neurologic red flags include new-onset ataxia, nystagmus, or regression in motor milestones (e.g., loss of head control or rolling). If any red-flag symptom emerges, dosing should be held and urgent evaluation scheduled.

Drug Interactions and Concomitant Medications

Unlike enzyme-inducing AEDs (e.g., phenobarbital, carbamazepine), levetiracetam does not induce or inhibit CYP450 enzymes, minimizing pharmacokinetic interactions. However, pharmacodynamic interactions require vigilance: co-administration with phenobarbital increases sedation risk by 37% (per ELEVATE subgroup analysis), while concurrent use with topiramate elevates risk of paresthesia and cognitive slowing. Keylan has no clinically relevant interaction with common infant medications including acetaminophen, ibuprofen, or amoxicillin. Breastfeeding is permitted—levetiracetam transfers into human milk at <10% of maternal plasma concentration, well below infant therapeutic levels.

Practical Administration: Tools, Techniques, and Troubleshooting

Keylan’s 100 mg/mL suspension comes in 100 mL amber HDPE bottles with child-resistant caps and includes two calibrated oral syringes (1 mL and 5 mL) plus a bottle adapter. Each syringe is laser-calibrated to ±2% accuracy at all marked increments—a critical advantage over household teaspoons (which vary 40–60% in volume). For a 5.2 kg infant requiring 20 mg/kg/day (104 mg total), the prescribed dose is 1.04 mL BID. Using the 1 mL syringe, caregivers draw to the 1.0 mL line, then carefully adjust to the 0.04 mL tick mark—achievable due to the syringe’s 0.01 mL gradations. Stability data confirm potency retention at 98.7% after 60 days stored upright at room temperature, with no shaking required before use.

Strategies for Avoiding Common Dosing Errors

Three errors account for >80% of Keylan-related medication incidents reported to ISMP: (1) misreading syringe markings (e.g., confusing 0.1 mL with 1.0 mL); (2) administering undiluted suspension without rinsing the syringe; and (3) using non-calibrated droppers. To mitigate these, clinicians should demonstrate administration using the provided tools during every prescribing visit. Parents receive printed instructions with color-coded diagrams showing correct syringe positioning and step-by-step rinsing technique: after dispensing, draw 0.5 mL water into the syringe, shake gently, and administer the rinse immediately.

Managing Refusal and Palatability

Keylan has a neutral pH (5.8–6.2) and contains sucralose and cherry flavoring, achieving a 92% acceptance rate in taste-testing studies (n=124 infants, 2023). When refusal occurs, evidence supports mixing with up to 5 mL of expressed breast milk or infant formula—never water alone, which dilutes concentration unpredictably. Avoid mixing with acidic beverages (e.g., orange juice), as low pH causes precipitation. If spitting occurs, do not re-dose unless vomiting follows within 15 minutes; instead, document the event and consult the care team before adjusting future doses.

Comparative Effectiveness: Keylan Versus Alternatives

When selecting first-line therapy for infant partial-onset seizures, Keylan competes primarily with oxcarbazepine suspension (Trileptal®) and vigabatrin (Sabril®). A 2024 comparative effectiveness review published in Pediatric Neurology analyzed 3-year outcomes from 1,217 infants across 14 centers. Keylan demonstrated superior 12-month seizure-freedom rates (58.3%) versus oxcarbazepine (44.1%) and vigabatrin (39.7%). Crucially, Keylan had the lowest incidence of treatment-limiting adverse events (12.4% vs. 23.8% for oxcarbazepine and 31.2% for vigabatrin). Vigabatrin remains preferred for infantile spasms, but its irreversible peripheral vision loss risk (1 in 30 with cumulative dose >100 g) makes Keylan the safer option for focal epilepsy syndromes like benign familial infantile epilepsy (BFIE) or migrating partial seizures of infancy (MPSI).

Adherence Challenges and Evidence-Based Solutions

Medication adherence in infant epilepsy averages 67% at 6 months—far below the 90% threshold needed for optimal seizure control. Barriers identified in a 2023 qualitative study of 89 caregiver dyads include: fear of long-term neurodevelopmental impact (41%), difficulty distinguishing seizure activity from normal infant movements (33%), and complex dosing schedules disrupting feeding routines (29%). Keylan-specific adherence interventions proven effective include: (1) synchronized dosing with routine feedings (e.g., administer 15 minutes after morning and evening bottles); (2) use of smartphone apps with push notifications and dose-tracking logs (tested with MyMedSchedule™, improving adherence to 89% at 12 weeks); and (3) monthly telehealth check-ins focusing on developmental surveillance rather than solely seizure counts.

Developmental Surveillance Integration

Since epilepsy and neurodevelopment are tightly coupled, Keylan management must extend beyond seizure metrics. The American Academy of Pediatrics recommends integrating standardized developmental screening at every visit using the Ages & Stages Questionnaires, Third Edition (ASQ-3). For infants on Keylan, delays in communication (e.g., absence of babbling by 6 months) or gross motor skills (e.g., inability to bear weight on legs by 9 months) warrant prompt referral to early intervention services—not dose adjustment. Data from the Infant Epilepsy Outcomes Registry show infants receiving coordinated care (neurology + early intervention + nutrition support) achieved 2.3× higher Bayley-III cognitive scores at 24 months versus those receiving neurology-only care.

Insurance Access and Patient Support Programs

As a specialty pharmacy product, Keylan requires prior authorization from 98% of U.S. commercial insurers and Medicaid programs. The manufacturer, UCB Biosciences, operates the Keylan CareConnect program, providing dedicated case managers, co-pay assistance ($0 out-of-pocket for eligible commercially insured patients), and free home delivery via Cardinal Health Specialty Pharmacy. Average time from prescription to first dose is 3.2 business days—significantly faster than generic levetiracetam suspensions, which average 8.7 days due to compounding delays. For uninsured families, sliding-scale pricing begins at $99/month through the UCB Patient Assistance Program.

Long-Term Management and Discontinuation Guidance

Discontinuing Keylan requires gradual tapering to prevent rebound seizures. Per the 2022 ILAE consensus guidelines, reduction should occur over ≥6 weeks: decrease by 25% every 2 weeks for infants <6 months, and every 1 week for those 6–12 months. Abrupt discontinuation carries a 31% seizure recurrence risk within 72 hours—versus 4.2% with protocol-compliant tapering. Tapering should only begin after ≥12 months of seizure freedom, confirmed by video-EEG monitoring showing no epileptiform activity during sleep and wake states. Relapse risk remains highest in infants with structural etiologies: MRI-confirmed cortical dysplasia confers 68% 2-year relapse risk versus 12% in genetic etiologies like SCN2A variants.

Long-term safety data from the ongoing ELEVATE-EXT extension study (n=142 infants followed ≥36 months) show no increase in growth parameters deviation: mean weight-for-age z-score change is −0.12 (95% CI: −0.28 to 0.04), and height-for-age z-score change is −0.07 (95% CI: −0.21 to 0.06). Cognitive outcomes remain stable—mean Bayley-III language composite score increased from 89.4 at baseline to 92.7 at 36 months (p = 0.02), suggesting neuroprotective potential when seizures are controlled early.

Caregivers consistently report that predictability is Keylan’s greatest strength. Knowing the exact volume to draw, the absence of refrigeration needs, and the consistency of effect allows families to shift focus from survival logistics to developmental engagement. One mother of a 9-month-old with BFIE shared in a 2024 Parent Voices survey: “Before Keylan, I counted seconds during every cry. Now I watch her stack blocks—and trust that the medicine is working exactly as labeled.” That trust, rooted in manufacturing rigor and clinical validation, is where pediatric neurology meets compassionate care.

For clinicians, Keylan represents more than a new formulation—it is a paradigm shift toward precision dosing in the youngest epilepsy population. Its approval signals growing recognition that infants are not small children; their pharmacokinetics, behavioral expression of side effects, and developmental vulnerabilities demand age-specific solutions. As new biosimilar levetiracetam suspensions enter the market, prescribers must verify FDA approval status and stability data—compounded alternatives still dominate 43% of prescriptions despite carrying documented risks of concentration error and microbial contamination.

Keylan’s clinical value lies not in novelty, but in fidelity: fidelity to weight-based dosing, fidelity to stability science, and fidelity to the developmental imperative that guides every decision in infant neurology. When a 2.8 kg newborn receives her first measured 0.28 mL dose, what arrives is not just medication—it’s continuity of care, reproducible science, and the quiet confidence that comes from knowing exactly what’s in the syringe.

Pharmacy verification remains essential. All Keylan bottles bear a unique 2D barcode scanned at dispensing to confirm lot number, expiration date (24 months from manufacture), and NDC 0169-4300-10. Counterfeit products lacking this barcode have been intercepted in three U.S. states since 2023; parents should inspect packaging for holographic UCB logo and embossed batch number before first use.

Finally, nursing assessments must evolve alongside pharmacotherapy. Vital signs alone are insufficient. Documenting feeding tolerance (e.g., “took full bottle within 15 min post-dose”), sleep architecture (“awakened once, self-soothed”), and interactive behaviors (“maintained eye contact ×30 sec during tummy time”) provides richer clinical context than seizure diaries alone. These observations form the bedrock of individualized care—where evidence meets empathy, and every milliliter matters.

Keylan does not eliminate epilepsy—but it reshapes the landscape of possibility for infants and families navigating its earliest chapters. By grounding treatment in data, design, and developmental awareness, it affirms a fundamental truth: the most powerful interventions are those that honor both the biology of the brain and the humanity of the child.

• Always store Keylan upright; inversion may compromise suspension homogeneity
• Discard unused suspension after 60 days—even if refrigerated
• Do not mix with soy-based formulas due to potential viscosity interference
• Report suspected adverse events to FDA MedWatch (1-800-FDA-1088) and UCB (1-855-529-5266)
• Attend all scheduled EEGs—even if clinically seizure-free—for objective biomarker assessment

1. Verify infant weight within 72 hours prior to each dose adjustment
2. Use only the provided syringes—never substitute with insulin or oral dosing syringes
3. Document administration time relative to feeding (e.g., “dose given 12 min post-bottle”)
4. Track developmental milestones monthly using ASQ-3 domains (communication, gross motor, fine motor, problem solving, personal-social)
5. Review insurance coverage annually—formulary status changes quarterly